Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
4D Molecular Therapeutics Inc
(NQ:
FDMT
)
26.14
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 4D Molecular Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
January 29, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
January 23, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
January 04, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
What 6 Analyst Ratings Have To Say About 4D Molecular Therapeutics
July 31, 2023
Via
Benzinga
Analyst Ratings for 4D Molecular Therapeutics
July 05, 2023
Via
Benzinga
Analyst Ratings for 4D Molecular Therapeutics
June 08, 2023
Via
Benzinga
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
January 03, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
December 21, 2023
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.
Via
Benzinga
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
December 21, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
December 04, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
November 15, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
November 09, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
November 01, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
October 30, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
October 25, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD
October 23, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Abbott Laboratories, Nasdaq, Spirit AeroSystems And Other Big Stocks Moving Higher On Wednesday
October 18, 2023
U.S. stocks traded lower, with the Dow Jones falling around 50 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 20, 2023
Via
Benzinga
4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
September 12, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
September 07, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD
September 07, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights
August 09, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
July 29, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data
July 17, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Poised For Success: FDA Discussion And Solid Position In Competitive Genetic Medicine Space, Says Analyst
July 05, 2023
Chardan Research analyst Geulah Livshits initiated coverage on 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) with a Buy rating and
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023
July 05, 2023
Via
Benzinga
Why Oxford Industries Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 08, 2023
Gainers Baosheng Media Group Holdings Limited (NASDAQ: BAOS) shares climbed 91.2% to $10.81.
Via
Benzinga
Carvana, Designer Brands, REV Group And Other Big Stocks Moving Higher On Thursday
June 08, 2023
U.S. stocks traded higher, with the Nasdaq Composite rising around 70 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 08, 2023
Via
Benzinga
Why Semtech Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
June 08, 2023
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares rose 50.5% to $0.20 in pre-market trading after dropping 5% on Wednesday.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.